Prediction of creatinine clearance from plasma creatinine: comparison of five formulae.

Robertshaw, Mark; Lai, Kar‐Neng; Swaminathan, R.

doi:10.1111/j.1365-2125.1989.tb05427.x

Cited by 52 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1b) and were near linear with respect to C max and AUC ( Table 5). The plasma PI-88 PK profile was consistent with those observed in previous studies with linear elimination evident from the time of C max [5,34,40]. The maximum predose concentration reached was 1.5 µg/mL, which was consistent with the data from an earlier study of PI-88 alone [5].…”

Section: Pharmacokinetic Studiessupporting

confidence: 81%

“…Eligibility criteria were as follows: patients to have histological or cytopathological confirmed advanced malignancies refractory to or without standard therapy, age ≥18 years, Eastern Cooperative Oncology Group (ECOG) performance status <2, life expectancy >3 months, and adequate laboratory parameters such as neutrophil counts >1.5 × 10 9 /L, platelet counts >100 × 10 9 /L, prothrombin time <1.5 times the upper limit of normal (×ULN), normal APTT, calculated creatinine clearance >60 ml/min (Cock-croft-Gault formula) [9,40], bilirubin < ULN and liver enzyme levels <2.5 × ULN.…”

Section: Patient Selectionmentioning

confidence: 99%

See 1 more Smart Citation

A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies

Chow

Gustafson²,

O’Bryant³

et al. 2008

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Purpose-This study evaluated the safety, toxicity, pharmacological properties and biological activity of PI-88, a heparanase endoglycosidase enzyme inhibitor, with fixed weekly docetaxel in patients with advanced solid malignancies.Experimental design-This was a phase I study to determine the maximal-tolerated dose of escalating doses of PI-88 administered subcutaneously for 4 days per week, along with docetaxel 30 mg/m 2 given on days 1, 8, 15 of a 28-day schedule.Results-Sixteen patients received a total of 42 courses of therapy. No dose-limiting toxicities were observed despite escalation to the highest planned dose level of PI-88 (250 mg/day). Frequent minor toxicities included fatigue (38%), dysgeusia (28.5%), thrombocytopenia (12%), diarrhea (14%), nausea (12%), and emesis (10%) in the 42 courses. No significant bleeding complications were observed. One patient developed a positive anti-heparin antibody test/serotonin releasing assay with positive anti-platelet factor 4/PI-88 antibodies and grade 1 thrombocytopenia in cycle 5, and was withdrawn from the study without any sequelae. PI-88 plasma concentrations (mirrored by APTT) and urinary elimination were linear and dose-proportional. Docetaxel did not alter the pharmacokinetic (PK) profile of PI-88, nor did PI-88 affect docetaxel PK. No significant relationship was determined between plasma or urine FGF-2, or plasma VEGF levels and PI-88 dose/response. Although no objective responses were observed; 9 of the 15 evaluable patients had stable disease for greater than two cycles of therapy.Conclusion-PI-88 administered at 250 mg/day for 4 days each week for 3 weeks with docetaxel 30 mg/m 2 on days 1, 8 and 15, every 28 days, was determined to be the recommended dose level for phase II evaluation. This combination was well tolerated without severe toxicities or PK interactions.

show abstract

Section: Pharmacokinetic Studiessupporting

confidence: 81%

Section: Patient Selectionmentioning

confidence: 99%

A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies

Chow

Gustafson²,

O’Bryant³

et al. 2008

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…That value is close to the value found in more robust studies. 19 Therefore, even considering the easy application of formulae for estimating CrCl, the overlapping of two methods is only partial, and the probability of false positive and false negative results is high. In addition, the currently most used Cockcroft-Gault and MDRD formulae have been derived from populations with a high prevalence of renal dysfunction, and, thus, they do not reflect the situation of the general population.…”

Section: Resultsmentioning

confidence: 99%

Correlação entre a depuração plasmática de creatinina utilizando urina coletada durante 24 horas e 12 horas

Silva¹,

Molina²,

Rodrigues³

et al. 2010

J. Bras. Nefrol.

View full text Add to dashboard Cite

Introduction: Creatinine concentration in plasma has been used to evaluate renal function. However, the endogenous creatinine clearance (CrCl) is more sensitive to this goal. Objective: Correlate the CrCl calculated from urinary collects of 12 h and 24 h. Methods: Ninety five volunteers (34-64 y) collected the urine for 24 h into two bottles: night, from 7 am to 7 pm and day, from 6 am to 7 pm. A fasting blood sample was used to measure plasma creatinine. Correlation between variables was determined by Pearson method (r) and the agreement between night and 24 h CrCl was determined by the Bland-Altman plot. Results: Urines of 4 individuals were discarded because of collect errors. In the final sample (n = 91; 42 males), hypertension was found in 23 and diabetic in 5. The CrCl (mL/min/1.73 m 2 ) was slightly lower in females in the night (77.8 ± 22.7 versus 88.4 ± 23.6; p < 0.05) and similar in males (91.2 ± 22.9 versus 97.3 ± 30.9; p > 0.05). Strong correlations were observed between the CrCl calculated from the night and day urines and the 24 h (r = 0.85 and 0.83; respectively). Agreement between the CrCl calculated from night or day urine and the 24 h urine was observed, respectively, to 85 and 83 individuals. Conclusion: The 12 h urine, mainly obtained at night, gives CrCl values similar to those obtained in the 24 h collect. Since urine collect is easier to outpatients at night, this period should be chosen in the clinical evaluation of the glomerular filtration rate.

show abstract

“…This formula has been commonly used in several studies of CHF and renal function. 15,16 Anemia was defined according to the general accepted definition of the World Health Organization (WHO; hemoglobin Յ12 g/dL for women, Յ13 g/dL for men).…”

Section: Renal Function and Anemiamentioning

confidence: 99%

Levels of Hematopoiesis Inhibitor N -Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure

et al. 2005

View full text Add to dashboard Cite

Background— Anemia is common in patients with chronic heart failure (CHF) and is associated with a poor prognosis. However, only a minority of patients with CHF have impaired renal function or underlying hematinic deficiencies. It has been shown that inhibition of the renin-angiotensin system is associated with the development of anemia. The aim of the present study was to determine possible mechanisms linking anemia to renin-angiotensin system activity in CHF patients. Methods and Results— We initially evaluated 98 patients with advanced stable CHF who were treated with ACE inhibitors (left ventricular ejection fraction, 28±1%; age, 69±1 years; 80% male), 10 of whom had an unexplained anemia (normal hematinics and no renal failure). These 10 anemic patients were matched with 10 nonanemic patients in terms of age and left ventricular ejection fraction. Serum ACE activity was 73% lower in anemic CHF patients compared with nonanemic CHF patients ( P =0.018). Moreover, serum of these patients inhibited in vitro the proliferation of bone marrow–derived erythropoietic progenitor cells of healthy donors by 17% ( P =0.003). Levels of the hematopoiesis inhibitor N -acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), which is almost exclusively degraded by ACE, were significantly higher in anemic CHF patients and were clearly correlated to erythroid progenitor cell proliferation ( r =−0.64, P =0.001). Conclusions— Serum ACE activity is markedly lower in anemic CHF patients, and serum of these patients inhibits hematopoiesis. The clear correlation between Ac-SDKP and proliferation of erythroid progenitor cells suggests an inhibitory role of Ac-SDKP on hematopoiesis in CHF patients, which may explain the observed anemia in patients treated with ACE inhibitors.

show abstract

Prediction of creatinine clearance from plasma creatinine: comparison of five formulae.

Cited by 52 publications

References 15 publications

A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies

A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies

Correlação entre a depuração plasmática de creatinina utilizando urina coletada durante 24 horas e 12 horas

Levels of Hematopoiesis Inhibitor N -Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure

Contact Info

Product

Resources

About